---
title: The Exploratory Study of Electroacupuncture in the Treatment of Peripheral Neuropathy Induced by Platinum Based Chemotherapy Drugs
nct_id: NCT03048591
overall_status: UNKNOWN
phase: NA
sponsor: Tianjin Medical University Cancer Institute and Hospital
study_type: INTERVENTIONAL
primary_condition: Chemotherapy-induced Peripheral Neuropathy
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03048591.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03048591"
ct_last_update_post_date: 2018-02-12
last_seen_at: "2026-05-12T06:51:57.685Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# The Exploratory Study of Electroacupuncture in the Treatment of Peripheral Neuropathy Induced by Platinum Based Chemotherapy Drugs

**NCT ID:** [NCT03048591](https://clinicaltrials.gov/study/NCT03048591)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 72
- **Lead Sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Conditions:** Chemotherapy-induced Peripheral Neuropathy
- **Start Date:** 2018-02-10
- **Completion Date:** 2018-11-01
- **CT.gov Last Update:** 2018-02-12

## Brief Summary

Through the research to confirm the effectiveness and safety of using electroacupuncture in the treatment of chemotherapy-induced peripheral neuropathy.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 80 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

1. The histopathological and / or cellular pathology results prove malignancy of the tumor and the patient has received chemotherapy treatment before.
2. 15weeks after the completion of chemotherapy, the limbs are still feeling abnormal and the symptoms fulfill World Health Organization (WHO) grade 2 or more.
3. zubrod - Eastern Cooperative Oncology Group-WHO (ZPS) grade 0-2, cardiac function, liver function and renal function are not significantly abnormal, the survival period of the patient is expected to be more than 6 months.
4. Gender unrestricted, aged between 18 to 80 years old.
5. Voluntary participation in the study, will to sign informed consent, willing to comply with randomized grouping, will to follow-up.

Exclusion Criteria:

1. Patients who suffer from peripheral neuropathy due to infection, radiotherapy, HIV, chronic alcoholism, hypothyroidism, diabetes, paraneoplastic syndrome or other diseases; or are suffering from nervous system diseases.
2. Patients who are being treated with other drugs that may lead to neurotoxicity .
3. Patients with blood coagulation disorder.
4. Pregnancy and lactating women.
5. Patients with infection, scarring or defects near the acupoint sites.
6. Received intervention for the prevention and treatment of peripheral neuropathy 2 weeks before screening or has received traditional Chinese medicine (acupuncture, moxibustion, cupping, Chinese medicine therapy one month before.
```

## Arms

- **Electroacupuncture group** (EXPERIMENTAL)
- **control group** (NO_INTERVENTION)

## Interventions

- **electroacupuncture** (DEVICE) — Acupoint selection: Bilateral Hegu (LI4), Qu-chi (LI1) of upper limbs and bilateral Zusanli (ST36) ,Taichung (LR3)of lower limbs.

## Primary Outcomes

- **Quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy (QLQ-CIPN20)** _(time frame: 6 weeks)_

## Secondary Outcomes

- **Functional Assessment of Cancer Treatment - General scale（FACT-G）** _(time frame: 6 weeks)_

## Recent Field Changes (last 30 days)

- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03048591.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03048591*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*